aHUS Complement Panel, S and P AHUSD

Synonyms

Allscripts (AEHR) Order Name

Not Orderable

Sunrise Clinical Manager (SCM) Order Name

Atypical Hemolytic Uremic Syndrome Complement P

Clinical Info

Detecting deficiencies in the alternative pathway that can cause atypical-hemolytic uremic syndrome, dense deposit disease, and C3 glomerulonephritis

ORDERING GUIDANCE
This test should be performed prior to treatment initiation and in the absence of therapy with complement inhibitors, such as eculizumab or ravulizumab. Complement inhibitors will affect performance of these assays.

For evaluating patients with possible thrombotic microangiopathies (TMA), the recommended first-tier test is ADM13 / ADAMTS13 Activity and Inhibitor Profile, Plasma. This test should be a second-tier test for TMA.

For patients who have received eculizumab or need to monitor response to eculizumab therapy, the recommended test is ECUMP / Eculizumab Monitoring Panel, Serum. Soluble membrane attack complex (sMAC) should not be used as a standalone assay to monitor eculizumab efficiency.

Specimen Type

Container

Blue Top Tube

Collection Instructions

Serum and Plasma are required for this test
Container/Tube: Both Light Blue (3.3 % sodium citrate) AND Red Top Tube
Specimen: 1.5 mL citrated plasma ( 1 mL min) AND 1.5 mL serum (1 mL min)
Transport Temperature; Frozen
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge; 1500 x g for 10 minutes at 4 degrees C and aliquot plasma from Light Blue 3.2 % sodium citrate and serum from the Red tube. into plastic vial.
3. Freeze specimen within 30 minutes.

Patient Preparation:
1. Fasting preferred.
2. Samples should not be collected earlier than 48 hours following plasma exchange.

Transport Instructions

Specimen Stability

Plasma Na Cit 14 Days Frozen
Serum Red top 14 Days Frozen

Methodology

Nephelometry
Automated Liposome Lysis Assay
Enzyme-Linked Immunosorbent Assay (ELISA)

Days Performed

TAT: 13 - 22 Days

Performing Laboratory

Mayo Medical Laboratories

CPT

86160 x 7
86161
86162

PDM

225440

Result Interpretation

FACTOR B COMPLEMENT ANTIGEN                     15.2-42.3 mg/dL

SC5b-9 COMPLEMENT                                            < or =250 ng/mL

FACTOR H COMPLEMENT ANTIGEN                  18.5 to 40.8 mg/dL

C4d COMPLEMENT ACTIVATION FRAGMENT     < or =9.8 mcg/mL

CBb COMPLEMENT ACTIVATION FRAGMENT     < or =1.6 mcg/mL

COMPLEMENT C4                                                           14-40 mg/dL

COMPLEMENT C3                                                         75-175 mg/dL

ALTERNATIVE COMPLEMENT, PATHWAY (AH50) FUNCTIONAL

                                                                                  > or =46% normal

COMPLEMENT, TOTAL                                                     30-75 U/mL

Forms